153individually attributable records; residual overlap possible in 8
1 / 109had exact patient-level CRS grade ≥3; unknown grades are excluded
11 momedian follow-up among 118 records that report it
206
literature records shown
153
individually attributable
53
confirmed re-reports shown
11 mo
median FU (n=118)
1/109
CRS grade ≥3 / exact grades
8
possible-overlap flags
Modality
Disease
Outcome
Source
Options
Outcomes by publication year
Hatched = re-reports of patients already counted. Watch 2021–22 (only re-reports) and the hatched tops disappear when you collapse them. Bars normalised to 100%.
Off-therapy remission / major responseRemission, on RxResponse (not formal remission)Partial responseNo responseToo early / NRre-report
Show data table (accessible view)
| Source | Year | PMID(s) | Disease | Modality | Target | Response state | Therapy status | Display bucket | FU | CRS | Record status | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ↺ | Mougiakakos et al. | 2021 | PMID 34347960 | SLE (WHO class IIIA lupus nephritis with nephrotic syndrome; | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | 1.5 | 0 | Prior re-report / subsumed record |
| ↺ | Mackensen et al. | 2022 | PMID 36109639 | SLE | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | 17 | NR | Prior re-report / subsumed record |
| ↺ | Mackensen et al. | 2022 | PMID 36109639 | SLE | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | NR | Prior re-report / subsumed record | |
| ↺ | Mackensen et al. | 2022 | PMID 36109639 | SLE | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | NR | Prior re-report / subsumed record | |
| ↺ | Mackensen et al. | 2022 | PMID 36109639 | SLE | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | NR | Prior re-report / subsumed record | |
| ↺ | Mackensen et al. | 2022 | PMID 36109639 | SLE | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | NR | Prior re-report / subsumed record | |
| Pecher et al. | 2023 | PMID 37367976 | Antisynthetase syndrome (anti-Jo-1+) with myositis and ILD, | Autologous CAR-T | CD19 | Source-defined remission | On therapy | Remission, on Rx | 8 | 1 | Individually attributable record | |
| ↺ | Müller et al. | 2023 | PMID 36930673 | Anti-Jo1 antisynthetase syndrome with myositis and interstit | Autologous CAR-T | CD19 | Source-defined remission | On therapy | Remission, on Rx | 8 | 1 | Prior re-report / subsumed record |
| Sheng et al. | 2023 | PMID 38173731 | Sjogren's disease (with concurrent DLBCL) | Autologous CAR-T | CD19 | Disease-specific major/good response | Off therapy | Response (not formal remission) | 8 | 2 | Individually attributable record | |
| ↺ | Nunez et al. | 2023 | PMID 37744005 | SLE (refractory) | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | 3 | NR | Prior re-report / subsumed record |
| ↺ | Nunez et al. | 2023 | PMID 37744005 | SLE (refractory) | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | 3 | NR | Prior re-report / subsumed record |
| ↺ | Nunez et al. | 2023 | PMID 37744005 | SLE (refractory) | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | 3 | NR | Prior re-report / subsumed record |
| ↺ | Nunez et al. | 2023 | PMID 37744005 | SLE (refractory) | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | 3 | NR | Prior re-report / subsumed record |
| ↺ | Nunez et al. | 2023 | PMID 37744005 | SLE (refractory) | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | 3 | NR | Prior re-report / subsumed record |
| ↺ | Nunez et al. | 2023 | PMID 37744005 | SLE (refractory) | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | 3 | NR | Prior re-report / subsumed record |
| ↺ | Pecher et al. (target seed labeled "Müller") | 2023 | PMID 37367976 | Antisynthetase syndrome (anti-Jo-1; myositis + interstitial | Autologous CAR-T | CD19 | Source-defined remission | On therapy | Remission, on Rx | 8 | 1 | Confirmed duplicate / overlap |
| ↺ | Bergmann et al. | 2023 | PMID 37147112 | Diffuse cutaneous SSc (anti-RNA polymerase III / RP11+), wit | Autologous CAR-T | CD19 | Disease-specific major/good response | Off therapy | Response (not formal remission) | 6 | 1 | Prior re-report / subsumed record |
| Müller, Taubmann, Mackensen, Schett, et al. | 2024 | PMID 38381673 | SLE | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | 29 | 0 | Individually attributable record | |
| Müller, Taubmann, Mackensen, Schett, et al. | 2024 | PMID 38381673 | SLE | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | 25 | 1 | Individually attributable record | |
| Müller, Taubmann, Mackensen, Schett, et al. | 2024 | PMID 38381673 | SLE | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | 21 | 1 | Individually attributable record | |
| Müller, Taubmann, Mackensen, Schett, et al. | 2024 | PMID 38381673 | SLE | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | 19 | 1 | Individually attributable record | |
| Müller, Taubmann, Mackensen, Schett, et al. | 2024 | PMID 38381673 | SLE | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | 15 | 0 | Individually attributable record | |
| Müller, Taubmann, Mackensen, Schett, et al. | 2024 | PMID 38381673 | SLE | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | 15 | 1 | Individually attributable record | |
| Müller, Taubmann, Mackensen, Schett, et al. | 2024 | PMID 38381673 | SLE | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | 12 | 0 | Individually attributable record | |
| Müller, Taubmann, Mackensen, Schett, et al. | 2024 | PMID 38381673 | SLE | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | 6 | 1 | Individually attributable record | |
| Müller, Taubmann, Mackensen, Schett, et al. | 2024 | PMID 38381673 | Idiopathic inflammatory myositis (antisynthetase, Jo-1) | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | 18 | 1 | Individually attributable record | |
| Müller, Taubmann, Mackensen, Schett, et al. | 2024 | PMID 38381673 | Idiopathic inflammatory myositis (antisynthetase, Jo-1/Pm-Sc | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | 18 | 1 | Individually attributable record | |
| Müller, Taubmann, Mackensen, Schett, et al. | 2024 | PMID 38381673 | Idiopathic inflammatory myositis (antisynthetase, PL-7) | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | 5 | 2 | Individually attributable record | |
| Müller, Taubmann, Mackensen, Schett, et al. | 2024 | PMID 38381673 | Systemic sclerosis (RNAP III) | Autologous CAR-T | CD19 | Disease-specific major/good response | Off therapy | Response (not formal remission) | 13 | 1 | Individually attributable record | |
| Müller, Taubmann, Mackensen, Schett, et al. | 2024 | PMID 38381673 | Systemic sclerosis (Scl70) | Autologous CAR-T | CD19 | Disease-specific major/good response | Off therapy | Response (not formal remission) | 10 | 1 | Individually attributable record | |
| Müller, Taubmann, Mackensen, Schett, et al. | 2024 | PMID 38381673 | Systemic sclerosis (Scl70) | Autologous CAR-T | CD19 | Disease-specific major/good response | Off therapy | Response (not formal remission) | 7 | 1 | Individually attributable record | |
| Müller, Taubmann, Mackensen, Schett, et al. | 2024 | PMID 38381673 | Systemic sclerosis (Scl70) | Autologous CAR-T | CD19 | Disease-specific major/good response | Off therapy | Response (not formal remission) | 4 | 0 | Individually attributable record | |
| Wang et al. | 2024 | PMID 38777376 PMID 41612420 | SLE + comorbid DLBCL | Autologous CAR-T | CD19/BCMA | Source-defined remission | Off therapy | Off-therapy remission / major response | 67 | NR | Individually attributable record | |
| Wang et al. | 2024 | PMID 38777376 PMID 41612420 | SLE + comorbid DLBCL | Autologous CAR-T | CD19/BCMA | Source-defined remission | Off therapy | Off-therapy remission / major response | 67 | NR | Individually attributable record | |
| Wang et al. | 2024 | PMID 38777376 PMID 41612420 | Lupus nephritis IV-G(A/C)+V | Autologous CAR-T | CD19/BCMA | Source-defined remission | Off therapy | Off-therapy remission / major response | 33 | NR | Individually attributable record | |
| Wang et al. | 2024 | PMID 38777376 PMID 41612420 | Lupus nephritis class V | Autologous CAR-T | CD19/BCMA | Source-defined remission | Off therapy | Off-therapy remission / major response | 30 | NR | Individually attributable record | |
| Wang et al. | 2024 | PMID 38777376 PMID 41612420 | Lupus nephritis IV-G(A/C) | Autologous CAR-T | CD19/BCMA | Source-defined remission | Off therapy | Off-therapy remission / major response | 30 | NR | Individually attributable record | |
| Wang et al. | 2024 | PMID 38777376 PMID 41612420 | Lupus nephritis IV-G(A/C)+V | Autologous CAR-T | CD19/BCMA | Disease-specific major/good response | Off therapy | Response (not formal remission) | 30 | NR | Individually attributable record | |
| Wang et al. | 2024 | PMID 38777376 PMID 41612420 | Lupus nephritis IV-G(A/C)+V | Autologous CAR-T | CD19/BCMA | Source-defined remission | Off therapy | Off-therapy remission / major response | 30 | NR | Individually attributable record | |
| Wang et al. | 2024 | PMID 38777376 PMID 41612420 | Lupus nephritis IV-G(A/C) | Autologous CAR-T | CD19/BCMA | Source-defined remission | Off therapy | Off-therapy remission / major response | 24 | NR | Individually attributable record | |
| Wang et al. | 2024 | PMID 38777376 PMID 41612420 | SLE / lupus nephritis | Autologous CAR-T | CD19/BCMA | Source-defined remission | Off therapy | Off-therapy remission / major response | 24 | NR | Individually attributable record | |
| Wang et al. | 2024 | PMID 38777376 PMID 41612420 | Lupus nephritis IV-G(A/C)+V | Autologous CAR-T | CD19/BCMA | Source-defined remission | Off therapy | Off-therapy remission / major response | 24 | NR | Individually attributable record | |
| Wang et al. | 2024 | PMID 38777376 | SLE / lupus nephritis | Autologous CAR-T | CD19/BCMA | Too early / not reported | Unknown | Too early / NR | NR | Individually attributable record | ||
| Wang et al. | 2024 | PMID 38777376 PMID 41612420 | Lupus nephritis IV-G(A/C) | Autologous CAR-T | CD19/BCMA | Source-defined remission | Off therapy | Off-therapy remission / major response | 24 | NR | Individually attributable record | |
| Wang et al. | 2024 | PMID 38777376 PMID 41612420 | Lupus nephritis class III(A/C) | Autologous CAR-T | CD19/BCMA | Source-defined remission | On therapy | Remission, on Rx | 24 | NR | Individually attributable record | |
| ↺ | Nicolai et al. | 2024 | PMID 38924652 | Juvenile dermatomyositis (JDM), severe chronically active, r | Autologous CAR-T | CD19 | Disease-specific major/good response | Off therapy | Response (not formal remission) | 8 | 1 | Confirmed duplicate / overlap |
| Wang et al. | 2024 | PMID 39013470 | Immune-mediated necrotizing myopathy (IMNM) | Allogeneic / universal CAR-T | CD19 | Disease-specific major/good response | Unknown | Response (not formal remission) | 6 | 0 | Individually attributable record | |
| Wang et al. | 2024 | PMID 39013470 | Diffuse cutaneous systemic sclerosis (dcSSc) | Allogeneic / universal CAR-T | CD19 | Disease-specific major/good response | Unknown | Response (not formal remission) | 6 | 0 | Individually attributable record | |
| Wang et al. | 2024 | PMID 39013470 | Diffuse cutaneous systemic sclerosis (dcSSc) | Allogeneic / universal CAR-T | CD19 | Disease-specific major/good response | Unknown | Response (not formal remission) | 6 | 0 | Individually attributable record | |
| Volkov et al. | 2024 | PMID 39245937 | Anti-SRP immune-mediated necrotizing myopathy (IMNM); 33-yea | Autologous CAR-T | CD19 | Disease-specific major/good response | Off therapy | Response (not formal remission) | 4 | 0 | Individually attributable record | |
| Merkt et al. | 2024 | PMID 38135464 PMID 39673062 | Scl70+ systemic sclerosis with progressive NSIP/pulmonary fi | Autologous CAR-T | CD19 | Disease-specific major/good response | Unknown | Response (not formal remission) | 11 | 1 | Individually attributable record | |
| ↺ | Claus et al. | 2024 | PMID 39673062 | Scl70+ diffuse cutaneous systemic sclerosis with progressing | Autologous CAR-T | CD19 | Disease-specific major/good response | Unknown | Response (not formal remission) | 18 | NR | Confirmed duplicate / overlap |
| Szabo et al. | 2024 | PMID 39448205 | Rheumatoid arthritis (D2T-RA, seropositive ACPA+/RF++), asso | Autologous CAR-T | CD20/CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | 12 | 1 | Individually attributable record | |
| Qin et al. | 2024 | PMID 38289960 | Anti-SRP IMNM (7-y refractory) with concomitant Sjogren synd | Autologous CAR-T | BCMA | Source-defined remission | Off therapy | Off-therapy remission / major response | 18 | 1 | Individually attributable record | |
| ↺ | Krickau et al. | 2024 | PMID 38642568 | SLE with rapidly progressive, dialysis-dependent lupus nephr | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | 6 | 0 | Confirmed duplicate / overlap |
| Wang et al. | 2024 | PMID 39690781 | SLE with lupus nephritis (class IV-G(A/C)) | Autologous CAR-T | CD19/BCMA | Source-defined remission | Off therapy | Off-therapy remission / major response | 24 | 1 | Individually attributable record · Possible unresolved overlap | |
| Friedberg et al. | 2024 | PMID 39393780 | SLE with triple-positive antiphospholipid syndrome (recurren | Autologous CAR-T | CD19 | Disease-specific major/good response | Unknown | Response (not formal remission) | 1 | Individually attributable record | ||
| Li, Zhang, Jiang, et al. | 2024 | PMID 39047248 | SLE-associated immune thrombocytopenia (ITP), refractory; SL | Autologous CAR-T | CD19 | Source-defined remission | On therapy | Remission, on Rx | 6 | 1 | Individually attributable record | |
| Hagen, Müller, ... Mackensen, Schett | 2024 | PMID 39615991 | CNS SLE — transverse myelitis with spastic paraplegia, plus | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | 3 | 0 | Individually attributable record · Possible unresolved overlap | |
| ↺ | Hagen M, et al. (Lancet Rheumatol) | 2025 | PMID 40318690 | Systemic lupus erythematosus (active lupus nephritis) | Autologous CAR-T | CD19 | Too early / not reported | Unknown | Too early / NR | NR | Prior re-report / subsumed record | |
| ↺ | Hagen M, et al. (Lancet Rheumatol) | 2025 | PMID 40318690 | Systemic sclerosis (prior myocardial involvement) | Autologous CAR-T | CD19 | Too early / not reported | Unknown | Too early / NR | NR | Prior re-report / subsumed record | |
| ↺ | Hagen M, et al. (Lancet Rheumatol) | 2025 | PMID 40318690 | Systemic sclerosis (prior myocardial involvement) | Autologous CAR-T | CD19 | Too early / not reported | Unknown | Too early / NR | NR | Prior re-report / subsumed record | |
| ↺ | Hagen M, et al. (Lancet Rheumatol) | 2025 | PMID 40318690 | Idiopathic inflammatory myopathy (interstitial lung disease) | Autologous CAR-T | CD19 | Too early / not reported | Unknown | Too early / NR | NR | Prior re-report / subsumed record | |
| ↺ | Hagen M, et al. (Lancet Rheumatol) | 2025 | PMID 40318690 | Systemic lupus erythematosus (interstitial lung disease) | Autologous CAR-T | CD19 | Too early / not reported | Unknown | Too early / NR | NR | Prior re-report / subsumed record | |
| ↺ | Hagen M, et al. (Lancet Rheumatol) | 2025 | PMID 40318690 | Systemic sclerosis (interstitial lung disease) | Autologous CAR-T | CD19 | Too early / not reported | Unknown | Too early / NR | NR | Prior re-report / subsumed record | |
| ↺ | Wang et al. | 2025 | PMID 40549291 | SLE overlap syndrome with Class III lupus nephritis (10-year | Autologous CAR-T | CD19/BCMA | Source-defined remission | Off therapy | Off-therapy remission / major response | 18 | 1 | Prior re-report / subsumed record |
| ↺ | Müller et al. | 2025 | PMID 40245922 | Anti-Jo-1 antisynthetase syndrome / IIM with severe progress | Autologous CAR-T | CD19/BCMA | Source-defined remission | Off therapy | Off-therapy remission / major response | 9 | 1 | Prior re-report / subsumed record |
| Haase et al. | 2025 | PMID 40268741 | Antisynthetase syndrome (anti-Jo1), refractory incl. daratum | Autologous CAR-T | CD19 | Source-defined remission | On therapy | Remission, on Rx | 6 | 2 | Individually attributable record | |
| Wang et al. | 2025 | PMID 40562027 | Diffuse cutaneous systemic sclerosis (severe, dcSSc) | CAR-NK | CD19/BCMA | Disease-specific major/good response | Unknown | Response (not formal remission) | 6 | 0 | Individually attributable record | |
| Albach et al. | 2025 | PMID 39928370 | Overlap: diffuse SSc (Scl-70+) + ACPA+ RA | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | 6 | 2 | Individually attributable record | |
| ↺ | París-Muñoz et al. | 2025 | PMID 40306284 | Anti-MDA5 dermatomyositis (juvenile DM) with rapidly progres | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | 11 | 0 | Prior re-report / subsumed record |
| ↺ | Minopoulou et al. | 2025 | PMID 39893102 | PR3-ANCA+ granulomatosis with polyangiitis (GPA), multi-orga | Autologous CAR-T | CD19 | Source-defined remission | On therapy | Remission, on Rx | 4.3 | 1 | Prior re-report / subsumed record |
| Lodka & Schreiber | 2025 | PMID 41393856 | PR3-ANCA GPA (refractory; lung, kidney, joints, skin, sinona | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | 4.3 | 1 | Individually attributable record | |
| Lodka & Schreiber | 2025 | PMID 41393856 | PR3-ANCA GPA (refractory pulmonary disease) | Autologous CAR-T | CD19 | Source-defined remission | On therapy | Remission, on Rx | 9.9 | 0 | Individually attributable record | |
| Lodka & Schreiber | 2025 | PMID 41393856 | MPO-ANCA AAV (crescentic glomerulonephritis, kidney involvem | Autologous CAR-T | CD19 | Source-defined remission | On therapy | Remission, on Rx | 1.4 | NR | Individually attributable record | |
| Wang et al. | 2025 | PMID 40446794 | SLE (refractory, severe, multi-organ) | Allogeneic / universal CAR-T | CD19 | Disease-specific major/good response | On therapy | Response (not formal remission) | 12 | 0 | Individually attributable record | |
| Wang et al. | 2025 | PMID 40446794 | SLE (refractory, severe, multi-organ) | Allogeneic / universal CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | 12 | 0 | Individually attributable record | |
| Wang et al. | 2025 | PMID 40446794 | SLE (refractory, severe, multi-organ) | Allogeneic / universal CAR-T | CD19 | Disease-specific major/good response | On low-dose glucocorticoid | Response (not formal remission) | 12 | 0 | Individually attributable record | |
| Yang et al. | 2025 | PMID 40341741 | SLE (prior lupus cerebritis 2018; no active CNS lupus at enr | Allogeneic / universal CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | 6 | 1 | Individually attributable record | |
| Yang et al. | 2025 | PMID 40341741 | SLE (prior lupus cerebritis 2019; no active CNS lupus at enr | Allogeneic / universal CAR-T | CD19 | Source-defined remission | On therapy | Remission, on Rx | 6 | 1 | Individually attributable record | |
| Yang et al. | 2025 | PMID 40341741 | SLE (prior lupus cerebritis 2021; no active CNS lupus at enr | Allogeneic / universal CAR-T | CD19 | Source-defined remission | On therapy | Remission, on Rx | 6 | 1 | Individually attributable record | |
| Yang et al. | 2025 | PMID 40341741 | SLE (refractory; prior telitacicept) | Allogeneic / universal CAR-T | CD19 | Source-defined remission | On therapy | Remission, on Rx | 6 | 1 | Individually attributable record | |
| ↺ | Taubmann et al. | 2025 | PMID 40906188 | SLE (class IV lupus nephritis; severe multi-organ: vasculiti | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | NR | Prior re-report / subsumed record | |
| Liu et al. | 2025 | PMID 40918126 | SLE + lupus nephritis + antiphospholipid syndrome + type B i | Autologous CAR-T | CD19 | Source-defined remission | On therapy | Remission, on Rx | 4 | 0 | Individually attributable record | |
| Wang X, Zhang Y, et al. (Xu H, corresponding) | 2025 | PMID 40866583 | SLE with lupus nephritis (ISN/RPS class IV+V) | STAR-T / other engineered T-cell | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | 9 | 1 | Individually attributable record · Possible unresolved overlap | |
| Wang X, Zhang Y, et al. (Xu H, corresponding) | 2025 | PMID 40866583 | SLE with lupus nephritis (ISN/RPS class III+V) | STAR-T / other engineered T-cell | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | 6 | 0 | Individually attributable record · Possible unresolved overlap | |
| Wang X, Zhang Y, et al. (Xu H, corresponding) | 2025 | PMID 40866583 | SLE with lupus nephritis (ISN/RPS class III+V) | STAR-T / other engineered T-cell | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | 6 | 1 | Individually attributable record · Possible unresolved overlap | |
| Wang X, Zhang Y, et al. (Xu H, corresponding) | 2025 | PMID 40866583 | SLE with lupus nephritis (ISN/RPS class IV+V) | STAR-T / other engineered T-cell | CD19 | Partial response | Off therapy | Partial response | 6 | 0 | Individually attributable record · Possible unresolved overlap | |
| Wang X, Zhang Y, et al. (Xu H, corresponding) | 2025 | PMID 40866583 | SLE with lupus nephritis (ISN/RPS class IV+V) | STAR-T / other engineered T-cell | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | 6 | 0 | Individually attributable record · Possible unresolved overlap | |
| Gao J, Li M, Sun M, et al. (Zhao/Yang, Changhai Hospital, Shanghai) | 2025 | PMID 41240964 | SLE with lupus nephritis (proteinuria, hematuria) | CAR-NK | CD19 | Source-defined remission | On therapy | Remission, on Rx | 18 | 0 | Individually attributable record | |
| Gao J, Li M, Sun M, et al. (Zhao/Yang, Changhai Hospital, Shanghai) | 2025 | PMID 41240964 | SLE (hematologic/bone-marrow, joints) | CAR-NK | CD19 | Source-defined remission | On therapy | Remission, on Rx | 15 | 0 | Individually attributable record | |
| Gao J, Li M, Sun M, et al. (Zhao/Yang, Changhai Hospital, Shanghai) | 2025 | PMID 41240964 | SLE with renal involvement (pyuria), MALE | CAR-NK | CD19 | Source-defined remission | On therapy | Remission, on Rx | 15 | 0 | Individually attributable record | |
| Gao J, Li M, Sun M, et al. (Zhao/Yang, Changhai Hospital, Shanghai) | 2025 | PMID 41240964 | SLE (skin, bone-marrow, joints) | CAR-NK | CD19 | Source-defined remission | On therapy | Remission, on Rx | 12 | 0 | Individually attributable record | |
| Gao J, Li M, Sun M, et al. (Zhao/Yang, Changhai Hospital, Shanghai) | 2025 | PMID 41240964 | SLE with lupus nephritis (proteinuria, hematuria, pyuria, va | CAR-NK | CD19 | Disease-specific major/good response | Unknown | Response (not formal remission) | 12 | 0 | Individually attributable record | |
| Gao J, Li M, Sun M, et al. (Zhao/Yang, Changhai Hospital, Shanghai) | 2025 | PMID 41240964 | SLE with lupus nephritis (pyuria, bone-marrow, joints) | CAR-NK | CD19 | Source-defined remission | On therapy | Remission, on Rx | 12 | 0 | Individually attributable record | |
| Gao J, Li M, Sun M, et al. (Zhao/Yang, Changhai Hospital, Shanghai) | 2025 | PMID 41240964 | SLE with lupus nephritis (proteinuria, hematuria, bone-marro | CAR-NK | CD19 | Source-defined remission | On therapy | Remission, on Rx | 12 | 1 | Individually attributable record | |
| Gao J, Li M, Sun M, et al. (Zhao/Yang, Changhai Hospital, Shanghai) | 2025 | PMID 41240964 | SLE (hematologic — chronic thrombocytopenia, joints) | CAR-NK | CD19 | Disease-specific major/good response | Unknown | Response (not formal remission) | 12 | 0 | Individually attributable record | |
| Gao J, Li M, Sun M, et al. (Zhao/Yang, Changhai Hospital, Shanghai) | 2025 | PMID 41240964 | SLE with lupus nephritis (pyuria, skin, joints) | CAR-NK | CD19 | Disease-specific major/good response | Unknown | Response (not formal remission) | 12 | 0 | Individually attributable record | |
| Gao J, Li M, Sun M, et al. (Zhao/Yang, Changhai Hospital, Shanghai) | 2025 | PMID 41240964 | SLE (skin, bone-marrow) | CAR-NK | CD19 | Source-defined remission | On therapy | Remission, on Rx | 11 | 0 | Individually attributable record | |
| Gao J, Li M, Sun M, et al. (Zhao/Yang, Changhai Hospital, Shanghai) | 2025 | PMID 41240964 | SLE (vascular) | CAR-NK | CD19 | Source-defined remission | On therapy | Remission, on Rx | 11 | 0 | Individually attributable record | |
| Gao J, Li M, Sun M, et al. (Zhao/Yang, Changhai Hospital, Shanghai) | 2025 | PMID 41240964 | SLE (skin, joints) | CAR-NK | CD19 | Source-defined remission | On therapy | Remission, on Rx | 11 | 0 | Individually attributable record | |
| Gao J, Li M, Sun M, et al. (Zhao/Yang, Changhai Hospital, Shanghai) | 2025 | PMID 41240964 | SLE (bone-marrow, joints) | CAR-NK | CD19 | Source-defined remission | On therapy | Remission, on Rx | 9 | 0 | Individually attributable record | |
| Gao J, Li M, Sun M, et al. (Zhao/Yang, Changhai Hospital, Shanghai) | 2025 | PMID 41240964 | SLE (skin, joints) | CAR-NK | CD19 | Source-defined remission | On therapy | Remission, on Rx | 9 | 0 | Individually attributable record | |
| Gao J, Li M, Sun M, et al. (Zhao/Yang, Changhai Hospital, Shanghai) | 2025 | PMID 41240964 | SLE (skin, joints) | CAR-NK | CD19 | Disease-specific major/good response | Unknown | Response (not formal remission) | 7 | 0 | Individually attributable record | |
| Gao J, Li M, Sun M, et al. (Zhao/Yang, Changhai Hospital, Shanghai) | 2025 | PMID 41240964 | SLE with lupus nephritis (proteinuria, pyuria) | CAR-NK | CD19 | Source-defined remission | On therapy | Remission, on Rx | 7 | 0 | Individually attributable record | |
| Gao J, Li M, Sun M, et al. (Zhao/Yang, Changhai Hospital, Shanghai) | 2025 | PMID 41240964 | SLE (joints) | CAR-NK | CD19 | Source-defined remission | On therapy | Remission, on Rx | 7 | 0 | Individually attributable record | |
| Gao J, Li M, Sun M, et al. (Zhao/Yang, Changhai Hospital, Shanghai) | 2025 | PMID 41240964 | SLE with lupus nephritis (proteinuria) | CAR-NK | CD19 | Partial response | Unknown | Partial response | 5 | 0 | Individually attributable record | |
| Feng, Huo, Hong, et al. (Hu/Huang) | 2025 | PMID 40993243 | SLE with lupus nephritis (class V), skin and joint involveme | Autologous CAR-T | CD19/BCMA | Source-defined remission | Off therapy | Off-therapy remission / major response | 1 | Individually attributable record | ||
| Feng, Huo, Hong, et al. (Hu/Huang) | 2025 | PMID 40993243 | SLE with lupus nephritis (class IV), skin and joint involvem | Autologous CAR-T | CD19/BCMA | Partial response | Unknown | Partial response | 1 | Individually attributable record | ||
| Feng, Huo, Hong, et al. (Hu/Huang) | 2025 | PMID 40993243 | SLE with lupus nephritis (class III+V), U1-RNP/Ro52/histone | Autologous CAR-T | CD19/BCMA | Disease-specific major/good response | Off therapy | Response (not formal remission) | 1 | Individually attributable record | ||
| Feng, Huo, Hong, et al. (Hu/Huang) | 2025 | PMID 40993243 | SLE with lupus nephritis (class IV), skin involvement | Autologous CAR-T | CD19/BCMA | Source-defined remission | Off therapy | Off-therapy remission / major response | 1 | Individually attributable record | ||
| Feng, Huo, Hong, et al. (Hu/Huang) | 2025 | PMID 40993243 | SLE (male) with lupus nephritis (class IV), joint and lung i | Autologous CAR-T | CD19/BCMA | Source-defined remission | Off therapy | Off-therapy remission / major response | 1 | Individually attributable record | ||
| Feng, Huo, Hong, et al. (Hu/Huang) | 2025 | PMID 40993243 | SLE, skin and joint involvement (no nephritis) | Autologous CAR-T | CD19/BCMA | Source-defined remission | Off therapy | Off-therapy remission / major response | 1 | Individually attributable record | ||
| Feng, Huo, Hong, et al. (Hu/Huang) | 2025 | PMID 40993243 | SLE, joint involvement (no nephritis) | Autologous CAR-T | CD19/BCMA | Source-defined remission | Off therapy | Off-therapy remission / major response | 1 | Individually attributable record | ||
| Feng, Huo, Hong, et al. (Hu/Huang) | 2025 | PMID 40993243 | SLE with lupus nephritis (class IV), skin involvement | Autologous CAR-T | CD19/BCMA | Source-defined remission | Off therapy | Off-therapy remission / major response | 1 | Individually attributable record | ||
| Feng, Huo, Hong, et al. (Hu/Huang) | 2025 | PMID 40993243 | SLE with lupus nephritis (class IV), skin and joint involvem | Autologous CAR-T | CD19/BCMA | Source-defined remission | Off therapy | Off-therapy remission / major response | 1 | Individually attributable record | ||
| Feng, Huo, Hong, et al. (Hu/Huang) | 2025 | PMID 40993243 | SLE with lupus nephritis (class IV), skin and joint involvem | Autologous CAR-T | CD19/BCMA | Source-defined remission | Off therapy | Off-therapy remission / major response | 1 | Individually attributable record | ||
| Feng, Huo, Hong, et al. (Hu/Huang) | 2025 | PMID 40993243 | SLE with myositis, skin and joint involvement (no nephritis) | Autologous CAR-T | CD19/BCMA | Source-defined remission | Off therapy | Off-therapy remission / major response | 1 | Individually attributable record | ||
| Feng, Huo, Hong, et al. (Hu/Huang) | 2025 | PMID 40993243 | SLE with lupus nephritis (class IV), skin and joint involvem | Autologous CAR-T | CD19/BCMA | Source-defined remission | Off therapy | Off-therapy remission / major response | 1 | Individually attributable record | ||
| Feng, Huo, Hong, et al. (Hu/Huang) | 2025 | PMID 40993243 | SLE with lupus nephritis (class V), skin and joint involveme | Autologous CAR-T | CD19/BCMA | Source-defined remission | Off therapy | Off-therapy remission / major response | 1 | Individually attributable record | ||
| Feng, Huo, Hong, et al. (Hu/Huang) | 2025 | PMID 40993243 | SLE with lupus nephritis (class III), skin/joint/lung involv | Autologous CAR-T | CD19/BCMA | Disease-specific major/good response | Off therapy | Response (not formal remission) | 1 | Individually attributable record | ||
| Feng, Huo, Hong, et al. (Hu/Huang) | 2025 | PMID 40993243 | SLE, skin and joint involvement (no nephritis) | Autologous CAR-T | CD19/BCMA | Source-defined remission | Off therapy | Off-therapy remission / major response | 1 | Individually attributable record | ||
| He et al. | 2025 | PMID 39561867 | Refractory pediatric SLE (>3 yr; rashes, ulcers, arthritis, | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | 5 | 1 | Individually attributable record | |
| He et al. | 2025 | PMID 39561867 | Pediatric SLE (>5 yr) with Class IV lupus nephritis (baselin | Autologous CAR-T | CD19 | Disease-specific major/good response | Off therapy | Response (not formal remission) | 4 | 1 | Individually attributable record | |
| Hu Z, Cai S, et al. (Dong L, senior) | 2025 | PMID 40681435 | Lupus nephritis, ISN/RPS class IV (SLE) | Autologous CAR-T | BCMA | Source-defined remission | Off therapy | Off-therapy remission / major response | 12 | 0 | Individually attributable record | |
| Hu Z, Cai S, et al. (Dong L, senior) | 2025 | PMID 40681435 | Lupus nephritis, ISN/RPS class III+V (SLE) | Autologous CAR-T | BCMA | Source-defined remission | Off therapy | Off-therapy remission / major response | 12 | 0 | Individually attributable record | |
| Hu Z, Cai S, et al. (Dong L, senior) | 2025 | PMID 40681435 | Lupus nephritis, ISN/RPS class IV (SLE) | Autologous CAR-T | BCMA | Disease-specific major/good response | Off therapy | Response (not formal remission) | 9 | 0 | Individually attributable record | |
| Hu Z, Cai S, et al. (Dong L, senior) | 2025 | PMID 40681435 | Lupus nephritis, ISN/RPS class III (SLE) | Autologous CAR-T | BCMA | Source-defined remission | Off therapy | Off-therapy remission / major response | 9 | 0 | Individually attributable record | |
| Hu Z, Cai S, et al. (Dong L, senior) | 2025 | PMID 40681435 | Lupus nephritis, ISN/RPS class IV+V (SLE) | Autologous CAR-T | BCMA | Source-defined remission | Off therapy | Off-therapy remission / major response | 9 | 0 | Individually attributable record | |
| Hu Z, Cai S, et al. (Dong L, senior) | 2025 | PMID 40681435 | Lupus nephritis, ISN/RPS class IV (SLE) | Autologous CAR-T | BCMA | Source-defined remission | Off therapy | Off-therapy remission / major response | 9 | 1 | Individually attributable record | |
| Hu Z, Cai S, et al. (Dong L, senior) | 2025 | PMID 40681435 | Lupus nephritis, ISN/RPS class IV (SLE) | Autologous CAR-T | BCMA | Disease-specific major/good response | Off therapy | Response (not formal remission) | 6 | 0 | Individually attributable record | |
| Cai et al. | 2025 | PMID 41109316 | IgG4-related disease (biopsy-proven, multiorgan; right lacri | Autologous CAR-T | BCMA | Source-defined remission | Off therapy | Off-therapy remission / major response | 9 | 0 | Individually attributable record | |
| Cai et al. | 2025 | PMID 41109316 | IgG4-related disease (biopsy-proven, multiorgan; left paroti | Autologous CAR-T | BCMA | Source-defined remission | Off therapy | Off-therapy remission / major response | 9 | 0 | Individually attributable record | |
| Keitel et al. | 2025 | PMID 41371348 | Multiorgan IgG4-RD (pancreas, hepatobiliary tract, lungs), t | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | 12 | 1 | Individually attributable record | |
| ↺ | Garantziotis et al. | 2026 | PMID 40701862 | Systemic lupus erythematosus (treatment-refractory) | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | NR | Prior re-report / subsumed record | |
| ↺ | Garantziotis et al. | 2026 | PMID 40701862 | Systemic lupus erythematosus (treatment-refractory) | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | NR | Prior re-report / subsumed record | |
| ↺ | Garantziotis et al. | 2026 | PMID 40701862 | Systemic lupus erythematosus (treatment-refractory) | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | NR | Prior re-report / subsumed record | |
| ↺ | Garantziotis et al. | 2026 | PMID 40701862 | Systemic lupus erythematosus (treatment-refractory) | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | NR | Prior re-report / subsumed record | |
| ↺ | Garantziotis et al. | 2026 | PMID 40701862 | Systemic lupus erythematosus (treatment-refractory) | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | NR | Prior re-report / subsumed record | |
| ↺ | Garantziotis et al. | 2026 | PMID 40701862 | Systemic lupus erythematosus (treatment-refractory) | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | NR | Prior re-report / subsumed record | |
| ↺ | Garantziotis et al. | 2026 | PMID 40701862 | Systemic lupus erythematosus (treatment-refractory) | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | NR | Prior re-report / subsumed record | |
| Becilli, Metzler, Bracaglia, et al. (Locatelli/De Benedetti/Schett senior) | 2026 | PMID 41644747 | Childhood-onset SLE (class II/V lupus nephritis, ILD + PAH, | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | 24 | NR | Individually attributable record | |
| Becilli, Metzler, Bracaglia, et al. (Locatelli/De Benedetti/Schett senior) | 2026 | PMID 41644747 | Juvenile dermatomyositis (calcinosis universalis; male, age | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | 24 | 1 | Individually attributable record | |
| Becilli, Metzler, Bracaglia, et al. (Locatelli/De Benedetti/Schett senior) | 2026 | PMID 41644747 | Childhood-onset SLE (class IV/V LN, ILD + diffuse alveolar h | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | 18 | NR | Individually attributable record | |
| Becilli, Metzler, Bracaglia, et al. (Locatelli/De Benedetti/Schett senior) | 2026 | PMID 41644747 | Juvenile dermatomyositis (calcinosis universalis, NXP2 histo | Autologous CAR-T | CD19 | Disease-specific major/good response | Off therapy | Response (not formal remission) | 12 | 1 | Individually attributable record | |
| Becilli, Metzler, Bracaglia, et al. (Locatelli/De Benedetti/Schett senior) | 2026 | PMID 41644747 | Juvenile dermatomyositis with ILD (age 5; mosaic trisomy 21/ | Autologous CAR-T | CD19 | Disease-specific major/good response | Off therapy | Response (not formal remission) | 9 | NR | Individually attributable record | |
| Becilli, Metzler, Bracaglia, et al. (Locatelli/De Benedetti/Schett senior) | 2026 | PMID 41644747 | Childhood-onset SLE, dialysis-dependent AKI (class IV LN, he | Autologous CAR-T | CD19 | Disease-specific major/good response | Off therapy | Response (not formal remission) | 24 | 1 | Individually attributable record | |
| Becilli, Metzler, Bracaglia, et al. (Locatelli/De Benedetti/Schett senior) | 2026 | PMID 41644747 | Childhood-onset SLE (class IV/V LN, hematologic, serositis; | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | 12 | NR | Individually attributable record | |
| Becilli, Metzler, Bracaglia, et al. (Locatelli/De Benedetti/Schett senior) | 2026 | PMID 41644747 | Juvenile systemic sclerosis (SCL-70/SSA/Ku positive, histori | Autologous CAR-T | CD19 | Disease-specific major/good response | Off therapy | Response (not formal remission) | 12 | NR | Individually attributable record | |
| Yang L, Wan X, et al. (Li BS senior author) | 2026 | PMID 41852345 | Post-HSCT warm AIHA with concurrent bone-marrow B-ALL relaps | Autologous CAR-T | CD19/CD22 | Source-defined remission | Off therapy | Off-therapy remission / major response | 39.3 | 0 | Individually attributable record | |
| Yang L, Wan X, et al. (Li BS senior author) | 2026 | PMID 41852345 | Post-HSCT warm AIHA (steroid/IVIG/bortezomib-refractory) wit | Autologous CAR-T | CD19/CD22 | Source-defined remission | Off therapy | Off-therapy remission / major response | 36.5 | 1 | Individually attributable record | |
| Yang L, Wan X, et al. (Li BS senior author) | 2026 | PMID 41852345 | Isolated refractory post-HSCT warm AIHA (no leukemia relapse | Autologous CAR-T | CD19/CD22 | Source-defined remission | Off therapy | Off-therapy remission / major response | 9.6 | 1 | Individually attributable record | |
| Rimar et al. | 2026 | PMID 41936079 | SCL-70-positive SSc (labeled limited cutaneous in text), NSI | Autologous CAR-T | CD19 | Disease-specific major/good response | Unknown | Response (not formal remission) | 12 | 1 | Individually attributable record | |
| Rimar et al. | 2026 | PMID 41936079 | RNA polymerase III-positive diffuse cutaneous SSc (dcSSc), N | Autologous CAR-T | CD19 | Disease-specific major/good response | Unknown | Response (not formal remission) | 11 | 0 | Individually attributable record | |
| Rimar et al. | 2026 | PMID 41936079 | RNA polymerase III-positive diffuse cutaneous SSc (dcSSc) wi | Autologous CAR-T | CD19 | No response | Unknown | No response | 11 | 0 | Individually attributable record | |
| Jia et al. | 2026 | PMID 42223209 | Progressive dcSSc (anti-Scl-70+; digital ulcers, arthritis, | Autologous CAR-T | CD19 | Disease-specific major/good response | Unknown | Response (not formal remission) | 9 | NR | Individually attributable record | |
| Jia et al. | 2026 | PMID 42223209 | SSc-myositis overlap (anti-fibrillarin+ and anti-Ku+; ILD, d | Autologous CAR-T | CD19 | Disease-specific major/good response | Unknown | Response (not formal remission) | 9 | NR | Individually attributable record | |
| Jia et al. | 2026 | PMID 42223209 | Progressive dcSSc (anti-Scl-70+; ILD, contractures) | Autologous CAR-T | CD19 | Disease-specific major/good response | Unknown | Response (not formal remission) | 9 | NR | Individually attributable record | |
| Jia et al. | 2026 | PMID 42223209 | Progressive dcSSc (anti-Scl-70+; highest mRSS, digital ulcer | Autologous CAR-T | CD19 | Disease-specific major/good response | Unknown | Response (not formal remission) | 9 | NR | Individually attributable record | |
| Jia et al. | 2026 | PMID 42223209 | Progressive dcSSc (low ANA 1:80, no SSc-specific autoantibod | Autologous CAR-T | CD19 | Disease-specific major/good response | Unknown | Response (not formal remission) | 9 | 3 | Individually attributable record | |
| Jia et al. | 2026 | PMID 42223209 | Progressive dcSSc (anti-fibrillarin+; ILD) | Autologous CAR-T | CD19 | Disease-specific major/good response | Unknown | Response (not formal remission) | 9 | NR | Individually attributable record | |
| ↺ | Müller et al. | 2026 | PMID 41501497 | SLE (lupus nephritis) | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | NR | Prior re-report / subsumed record | |
| ↺ | Müller et al. | 2026 | PMID 41501497 | SSc | Autologous CAR-T | CD19 | Too early / not reported | Off therapy | Too early / NR | 2 | Prior re-report / subsumed record | |
| ↺ | Müller et al. | 2026 | PMID 41501497 | SLE (lupus nephritis) | Autologous CAR-T | CD19 | Disease-specific major/good response | Off therapy | Response (not formal remission) | NR | Prior re-report / subsumed record | |
| ↺ | Müller et al. | 2026 | PMID 41501497 | IIM | Autologous CAR-T | CD19 | Partial response | Off therapy | Partial response | 9 | NR | Prior re-report / subsumed record |
| Jiang et al. | 2026 | PMID 41669912 | SLE with class IV lupus nephritis | Autologous CAR-T | CD19/BCMA | Source-defined remission | Off therapy | Off-therapy remission / major response | 30 | 1 | Individually attributable record · Possible unresolved overlap | |
| Kremer et al. | 2026 | PMID 41984818 | Seropositive RA / SSc overlap, with interstitial lung diseas | Autologous CAR-T | CD19 | Disease-specific major/good response | Unknown | Response (not formal remission) | 12 | NR | Individually attributable record | |
| París-Muñoz et al. | 2026 | PMID 42285038 | MDA5+ juvenile dermatomyositis with rapidly progressive ILD | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | 11 | 0 | Individually attributable record | |
| Schneider et al. | 2026 | PMID 41834136 | GPA (ANCA-associated vasculitis), relapsing/refractory, lung | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | 12 | 0 | Individually attributable record | |
| Korte et al. | 2026 | PMID 41962541 | Cold- and warm-agglutinin AIHA (refractory to 9 prior lines) | Autologous CAR-T | CD19 | Source-defined remission | On therapy | Remission, on Rx | 11 | 0 | Individually attributable record | |
| Shan et al. | 2026 | PMID 41935952 | SLE | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | NR | Individually attributable record | ||
| Shan et al. | 2026 | PMID 41935952 | SLE (high baseline activity, SLEDAI 10) | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | NR | Individually attributable record | ||
| Shan et al. | 2026 | PMID 41935952 | SLE (baseline SLEDAI-2K <4, on ≥7.5 mg/day prednisolone) | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | NR | Individually attributable record | ||
| Shan et al. | 2026 | PMID 41935952 | SLE (high baseline activity, SLEDAI 10) | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | NR | Individually attributable record | ||
| Shan et al. | 2026 | PMID 41935952 | SLE | Autologous CAR-T | CD19 | Disease-specific major/good response | Off therapy | Response (not formal remission) | NR | Individually attributable record | ||
| Shan et al. | 2026 | PMID 41935952 | SLE | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | NR | Individually attributable record | ||
| Shan et al. | 2026 | PMID 41935952 | SLE | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | NR | Individually attributable record | ||
| Shan et al. | 2026 | PMID 41935952 | SLE (baseline SLEDAI-2K <4) | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | NR | Individually attributable record | ||
| Shan et al. | 2026 | PMID 41935952 | SLE (baseline SLEDAI-2K <4) | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | NR | Individually attributable record | ||
| Shan et al. | 2026 | PMID 41935952 | SLE | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | NR | Individually attributable record | ||
| Shan et al. | 2026 | PMID 41935952 | SLE | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | NR | Individually attributable record | ||
| Shan et al. | 2026 | PMID 41935952 | SLE with lupus nephritis (grade IV-V) | Autologous CAR-T | CD19 | No response | Off therapy | No response | NR | Individually attributable record | ||
| Shan et al. | 2026 | PMID 41935952 | SLE | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | NR | Individually attributable record | ||
| Shan et al. | 2026 | PMID 41935952 | SLE | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | NR | Individually attributable record | ||
| Shan et al. | 2026 | PMID 41935952 | SLE with lupus nephritis | Autologous CAR-T | CD19 | No response | Off therapy | No response | NR | Individually attributable record | ||
| Shan et al. | 2026 | PMID 41935952 | SLE | Autologous CAR-T | CD19 | Disease-specific major/good response | Off therapy | Response (not formal remission) | NR | Individually attributable record | ||
| Shan et al. | 2026 | PMID 41935952 | SLE | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | NR | Individually attributable record | ||
| Shan et al. | 2026 | PMID 41935952 | SLE | Autologous CAR-T | CD19 | Source-defined remission | Off therapy | Off-therapy remission / major response | NR | Individually attributable record | ||
| Xu et al. | 2026 | PMID 42297600 | SLE (refractory) | Autologous CAR-T | CD19/BCMA | Source-defined remission | Off therapy | Off-therapy remission / major response | 12 | 0 | Individually attributable record | |
| Xu et al. | 2026 | PMID 42297600 | SLE (refractory) | Autologous CAR-T | CD19/BCMA | Disease-specific major/good response | Unknown | Response (not formal remission) | 12 | 0 | Individually attributable record | |
| Xu et al. | 2026 | PMID 42297600 | SLE (refractory) | Autologous CAR-T | CD19/BCMA | Source-defined remission | Off therapy | Off-therapy remission / major response | 12 | 0 | Individually attributable record | |
| Zhang C-x, et al. | 2026 | PMID 42414128 | Paediatric SLE with refractory immune thrombocytopenia | Autologous CAR-T | CD19/CD22 | Source-defined remission | Off therapy | Off-therapy remission / major response | 12 | 1 | Individually attributable record | |
| ↺ | Pecher, Henes, Henes, ... (Schett, Hagen) | 2026 | — | Systemic lupus erythematosus | Autologous CAR-T | CD19 | Too early / not reported | Unknown | Too early / NR | 12 | NR | Prior re-report / subsumed record |
| ↺ | Pecher, Henes, Henes, ... (Schett, Hagen) | 2026 | — | Systemic lupus erythematosus | Autologous CAR-T | CD19 | Too early / not reported | Unknown | Too early / NR | 12 | NR | Prior re-report / subsumed record |
| ↺ | Pecher, Henes, Henes, ... (Schett, Hagen) | 2026 | — | Systemic lupus erythematosus | Autologous CAR-T | CD19 | Too early / not reported | Unknown | Too early / NR | 12 | NR | Prior re-report / subsumed record |
| ↺ | Pecher, Henes, Henes, ... (Schett, Hagen) | 2026 | — | Systemic lupus erythematosus | Autologous CAR-T | CD19 | Too early / not reported | Unknown | Too early / NR | 12 | NR | Prior re-report / subsumed record |
| ↺ | Pecher, Henes, Henes, ... (Schett, Hagen) | 2026 | — | Systemic lupus erythematosus | Autologous CAR-T | CD19 | Too early / not reported | Unknown | Too early / NR | 12 | NR | Prior re-report / subsumed record |
| ↺ | Pecher, Henes, Henes, ... (Schett, Hagen) | 2026 | — | Systemic lupus erythematosus | Autologous CAR-T | CD19 | Too early / not reported | Unknown | Too early / NR | 12 | NR | Prior re-report / subsumed record |
| ↺ | Pecher, Henes, Henes, ... (Schett, Hagen) | 2026 | — | Systemic lupus erythematosus | Autologous CAR-T | CD19 | Too early / not reported | Unknown | Too early / NR | 12 | NR | Prior re-report / subsumed record |
| ↺ | Pecher, Henes, Henes, ... (Schett, Hagen) | 2026 | — | Systemic lupus erythematosus | Autologous CAR-T | CD19 | Too early / not reported | Unknown | Too early / NR | 12 | NR | Prior re-report / subsumed record |
| ↺ | Pecher, Henes, Henes, ... (Schett, Hagen) | 2026 | — | Systemic lupus erythematosus | Autologous CAR-T | CD19 | Too early / not reported | Unknown | Too early / NR | 12 | NR | Prior re-report / subsumed record |
| ↺ | Pecher, Henes, Henes, ... (Schett, Hagen) | 2026 | — | Systemic lupus erythematosus | Autologous CAR-T | CD19 | Too early / not reported | Unknown | Too early / NR | 12 | NR | Prior re-report / subsumed record |
| ↺ | Pecher, Henes, Henes, ... (Schett, Hagen) | 2026 | — | Systemic lupus erythematosus | Autologous CAR-T | CD19 | Too early / not reported | Unknown | Too early / NR | 12 | NR | Prior re-report / subsumed record |
| ↺ | Pecher, Henes, Henes, ... (Schett, Hagen) | 2026 | — | Systemic lupus erythematosus | Autologous CAR-T | CD19 | Too early / not reported | Unknown | Too early / NR | 12 | NR | Prior re-report / subsumed record |
| ↺ | Pecher, Henes, Henes, ... (Schett, Hagen) | 2026 | — | Systemic lupus erythematosus | Autologous CAR-T | CD19 | Too early / not reported | Unknown | Too early / NR | 12 | NR | Prior re-report / subsumed record |
| Dehdashtian et al. | 2026 | PMID 41850942 | SLE (refractory) | Autologous CAR-T | CD19 | Disease-specific major/good response | Off therapy | Response (not formal remission) | 5 | NR | Individually attributable record |